Study Highlights
- The genomic landscape of high versus low LILRB2 expressors varied widely by cancer type.
- LILRB2 expression was associated with biomarkers of response to immunotherapy such as PD-L1+ and an increased proportion of T cellinflamed tumors.
- High expression of LILRB2 was associated with improved time on treatment with pembrolizumab in Methods NSCLC.
Conclusions
- These data suggest that PDAC, NSCLC and UC tumors could potentially benefit from a combination of immune checkpoint inhibitors and LILRB2- blocking antibodies.